A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/22/2011	US20110311466 Novel 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics
12/22/2011	US20110311462 Compositions for treatment of ear disorders and methods of use thereof
12/22/2011	US20110311461 Alkaloid aminoester derivatives and medicinal composition thereof
12/22/2011	US20110311459 Alkaloid aminoester derivatives and medicinal composition thereof
12/22/2011	US20110311458 Alkaloid aminoester derivatives and medicinal compositions thereof
12/22/2011	US20110311455 Encapsulated agent guided imaging and therapies
12/22/2011	US20110311451 Synthesis of polymer conjugates of indolocarbazole compounds
12/22/2011	US20110311442 Direct cellular energy delivery system
12/22/2011	US20110308985 Composition of a liposomal gel containing hydrocortisone, its metabolites, precursors or mixtures thereof and the use thereof
12/22/2011	US20110308975 Stabilized pharmaceutical product
12/22/2011	US20110308519 Dry powder formulation comprising an antimuscarinic drug
12/22/2011	DE19836339B4 Kohlenhydratmischung Carbohydrate mix
12/22/2011	DE102010023949A1 In-situ Lecithin-Mikroemulsionsgel-Formulierung In-situ lecithin microemulsion formulation
12/22/2011	CA2802990A1 Asenapine maleate
12/22/2011	CA2802974A1 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
12/22/2011	CA2802957A1 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
12/22/2011	CA2802918A1 Process for the preparation of dronedarone
12/22/2011	CA2802874A1 Polymorphic forms of rifaximin
12/22/2011	CA2802873A1 Methods of treatment using tlr7 and/or tlr9 inhibitors
12/22/2011	CA2802853A1 Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
12/22/2011	CA2802831A1 Controlled release coat-core tablet
12/22/2011	CA2802761A1 Methods of treating or preventing estrogen-related diseases
12/22/2011	CA2802760A1 Transdermal administration of memantine
12/22/2011	CA2802714A1 Piperidinyl compound as a modulator of chemokine receptor activity
12/22/2011	CA2802692A1 Phenylthioacetate compounds, compositions and methods of use
12/22/2011	CA2802629A1 Substituted triazolopyridines
12/22/2011	CA2802615A1 Process for the preparation of glycopyrronium chloride
12/22/2011	CA2802588A1 Heteroaryl imidazolone derivatives as jak inhibitors
12/22/2011	CA2802584A1 Crystal form of glycopyrronium chloride
12/22/2011	CA2802535A1 Thioacetate compounds, compositions and methods of use
12/22/2011	CA2802529A1 Carbapenem antibacterials with gram-negative activity
12/22/2011	CA2802483A1 Crystal of amide compound
12/22/2011	CA2802477A1 Agent for treating hcv infection
12/22/2011	CA2802441A1 Use of isoacteoside or pharmaceutically acceptable salt thereof
12/22/2011	CA2802414A1 Agent for treating renal fibrosis
12/22/2011	CA2802407A1 Treatment of gout and hyperuricemia
12/22/2011	CA2802388A1 Compositions and methods for treating cancer
12/22/2011	CA2802188A1 D2 antagonists, methods of synthesis and methods of use
12/22/2011	CA2801934A1 Cyclohexyl-azetidinyl antagonists of ccr2
12/22/2011	CA2801930A1 Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
12/22/2011	CA2801712A1 Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution
12/22/2011	CA2801707A1 Ranolazine for use for the treatment of pulmonary hypertension
12/22/2011	CA2801581A1 Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders
12/22/2011	CA2801281A1 Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
12/22/2011	CA2801206A1 Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
12/22/2011	CA2801182A1 Gpr120 receptor agonists and uses thereof
12/22/2011	CA2801168A1 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators
12/22/2011	CA2801048A1 Antioxidant composition
12/22/2011	CA2800446A1 Solid ivabradine-containing composition
12/22/2011	CA2800444A1 Ivabradine-containing pharmaceutical composition
12/22/2011	CA2800442A1 Ivabradine-containing pharmaceutical composition with modified release
12/22/2011	CA2799489A1 An injectable dosage form of flupirtine
12/22/2011	CA2798150A1 New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions
12/22/2011	CA2797320A1 Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives
12/22/2011	CA2796774A1 Pharmaceutical combination for the treatment of pain
12/22/2011	CA2790294A1 .alpha.-crystalline form of carbabenzpyride
12/21/2011	EP2398178A1 Relay link HARQ operation
12/21/2011	EP2397551A1 Compounds and methods for modulating expression of PCSK9
12/21/2011	EP2397494A1 Human antibodies that bind human TNFalpha
12/21/2011	EP2397487A1 Short-chain cationic polyamino acid and use thereof
12/21/2011	EP2397482A1 Heteroaryl imidazolone derivatives as jak inhibitors
12/21/2011	EP2397481A1 Inhibitor of casein kinase 1delta and casein kinase 1epsilon
12/21/2011	EP2397480A1 Diazepinedione derivative
12/21/2011	EP2397479A1 Hetero ring derivative
12/21/2011	EP2397478A1 1,3-diaryl substituted ureas as modulators of kinase activity.
12/21/2011	EP2397477A1 Heterocyclic-substituted piperidine compounds and the uses thereof
12/21/2011	EP2397476A2 Indole derivative having PGD2 receptor antagonist activity
12/21/2011	EP2397473A1 A stable highly crystalline anacetrapib
12/21/2011	EP2397471A1 Benzimidazole compounds and their use
12/21/2011	EP2397469A1 Diarylhydantoin compounds
12/21/2011	EP2397462A2 Compounds, compositions and methods of treatment for heart failure
12/21/2011	EP2397458A1 Organic salts and co-crystals of phenylbutyric acid
12/21/2011	EP2397159A2 Combination of morphinan compounds and antidepressant for the treatment of intractable and chronic pain
12/21/2011	EP2397158A2 Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
12/21/2011	EP2397157A1 Brain tumor stem cell differentiation promoter, and therapeutic agent for brain tumor
12/21/2011	EP2397147A1 Feed for preventing and/or treating diseases due to clostridium sp. bacteria in livestock, and anti-clostridium agent
12/21/2011	EP2397144A1 Use of Isoacteoside in Preventing or Treating Amyloid Beta Peptide-Associated Diseases or Conditions, and Method for Inhibiting Formation, Accumulation or Aggregation of Amyloid Beta Peptides
12/21/2011	EP2397143A1 Freeze-dried preparation of tetrodotoxin and the producing method thereof
12/21/2011	EP2397142A2 Use of dpp iv inhibitors
12/21/2011	EP2397141A1 Process for the synthesis of beta-amino acids and derivatives thereof
12/21/2011	EP2397140A1 Compositions and methods for treating or preventing glaucoma or progression thereof
12/21/2011	EP2397139A1 Anti-neurodegenerative disease agent
12/21/2011	EP2397138A1 Method of inhibiting C-KIT kinase
12/21/2011	EP2397137A1 Use of inverse antagonists and/or agonists of cb1 receptors for preparing drugs to increase motor neurone excitability
12/21/2011	EP2397136A1 Anti-inflammatory composition
12/21/2011	EP2397135A1 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
12/21/2011	EP2397134A1 A pharmaceutical composition for treating diabetic nephropathy and the preparation method and use thereof
12/21/2011	EP2397133A2 Retinal derivatives and methods for the use thereof for the treatment of visual disorders
12/21/2011	EP2397132A2 Retinal derivatives and methods for the use thereof for the treatment of visual disorders
12/21/2011	EP2397131A2 Retinal derivatives and methods for the use thereof for the treatment of visual disorders
12/21/2011	EP2397130A2 Retinal derivatives and methods for the use thereof for the treatment of visual disorders
12/21/2011	EP2397129A1 Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
12/21/2011	EP2397128A1 Use of L-arginine optionally combined with magnesium for the treatment of sickle cell disease and/or pulmonary hypertension
12/21/2011	EP2397127A1 Use of creatine or creatine compounds for skin preservation
12/21/2011	EP2397126A1 Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses
12/21/2011	EP2397125A1 Antioxidant composition
12/21/2011	EP2397124A1 Transdermal delivery systems
12/21/2011	EP2397122A2 Formulations of neramexane dosage forms
12/21/2011	EP2397121A2 Pharmaceutical preparation containing Entacapone, Levodopa and Carbidopa
12/21/2011	EP2397118A1 Device for pressure bathing in gas-containing mist

1 ... 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 ... 7860